Aim: To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2015 and the Annual Treatment Report for 2010 on the outcomes of patients who started treatment in 2010. Methods: The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment was initiated in 2015 were analyzed retrospectively. Survival of the patients who started treatment in 2010 was analyzed by using the Kaplan-Meier, log-rank and Wilcoxson tests. The 5-year survival rates of the patients with cervical cancer were 92.1%, 74.2%, 52.0%, and 29.8% for stages I, II, III, and IV, respectively. The 5-year survival rates for the patients with endometrial cancer were 94.3%, 88.8%, 74.0% and 26.6% for stages I, II, III and IV, respectively. The 5-year survival rates for the patients with ovarian cancer (surface epithelial-stromal tumors) were 88.5%, 80.1%, 46.3% and 36.2% for stages I, II, III and IV, respectively. Conclusion: The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.
Introduction
Each year, the Japan Society of Obstetrics and Gynecology (JSOG) gathers and analyzes information on the clinicopathological factors and prognosis of patients from various participating institutions for the purpose of surveying gynecological malignancy trends in Japan. Here, we present the Annual Patient Report for 2015 comprising patient information gathered in 2015 on the number of patients with gynecological malignancies, stages and treatment methods. We also present the Annual Treatment Report for 2010 comprising the analysis of the prognosis of patients whose treatment was initiated in 2010. The data reported in this paper are the English version of those cited in a paper that has already been published in Japanese.
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Patients and Methods
The data of patients whose treatment was initiated in 2015 were analyzed retrospectively and summarized as the Annual Patient Report for 2015. We performed a follow-up study on patients whose treatment was initiated in 2010 and calculated the 5-year survival for each disease in the Annual Treatment Report for 2010.
This study was approved by the JSOG ethics committee.
Annual Patient Report for 2015
Our report included 13 172 patients with CIN3, 7527 with stages I-IV cervical cancer, 757 with atypical endometrial hyperplasia, 10 119 with stages I-IV endometrial cancer, 6424 with ovarian cancer and 2181 with ovarian borderline tumors. These patients were diagnosed histologically and treated at the 430 registered JSOG institutions, between January and December 2015. Clinical staging of the cervical cancers and surgical staging of the endometrial cancers were performed based on the FIGO 2008 staging system. Surgical staging of the ovarian cancers, including ovarian borderline tumors, was performed based on the FIGO 2014 staging system. For cervical cancer, the patient's age, clinical stage, histologic type and treatment information were registered. For endometrial, ovarian borderline tumor and ovarian cancers, the patient's age, surgical stage, histologic type and treatment information were registered. Patient information was anonymized and registered in the JSOG website by the various registered institutions.
The statistical analysis was performed by the Clinical Research, Innovation, and Education Center, Tohoku University Hospital, Sendai, Japan.
Annual Treatment Report for 2010
We performed follow-up studies of patients who were registered between January and December of 2010 by the 301 JSOG-registered institutions after 3 and 5 years. According to the Annual Treatment Report for 2010, 6574 patients with cervical cancer, 6659 with endometrial cancer and 4330 with ovarian cancer were registered, and the staging of the respective diseases was performed based on the FIGO 1998 staging system. As the reliability of the treatment outcomes decreases with an increase in patient loss to followup, data from institutions where the percentage of patients lost to follow-up exceeded 20%, according to the follow-up report were not used in the outcome analysis. For that reason, the data used in the prognosis analysis were from 4309 patents with cervical cancer, 5054 with endometrial cancer and 3423 with ovarian cancer. Personal information was anonymized and registered in the JSOG website by the various registered institutions.
Statistical Analysis
The overall survival rates were analyzed by the Kaplan-Meier method, and statistical significance was determined using the log-rank test and Wilcoxon test. 
Results
Annual patient report for 2015
Cervical cancer
Age distribution (Fig. 1) Histologic types (Table 1) . With regard to histologic types of cervical cancer, squamous cell carcinoma was found in 72.3% of the patients and was the most common cancer, followed by adenocarcinoma, which occurred in 20.5% of the patients. The other histologic types are presented in Table 1 .
Treatment (Fig. 2) . With regard to cervical cancer treatments, surgery alone was performed in 34.8% of the patients and was the most common treatment, followed by radiotherapy + chemotherapy (25.1%), radiotherapy alone (10.7%), surgery + chemotherapy (13.0%) and surgery + radiotherapy + chemotherapy (10.2%). The other treatment methods, shown in Fig. 2 , include immunotherapy and hormone therapy. Surgery was the most common treatment for patients with stage I cervical cancer. Radiotherapy was the common treatment, for approximately half of the patients with stage II cervical cancer.
Endometrial cancer
Age distribution (Fig. 3) . The age distribution of patients with endometrial cancer was as follows: 1656 (16.4%), 3019 (29.8%), 2790 (27.6%) and 1635 (16.2%) patients in the age group of 40-49, 50-59, 60-69 and 70-79 years, respectively. From these results, it is evident that endometrial cancer is most common among women in their 50s and 60s. In young women (below 40 years of age), endometrial cancer accounted for 4.6% of the overall cases.
Surgical stages. With regard to the stage of endometrial cancer, 73.3% of the patients were stage I (stage I A: 57.2%, I B: 15.9%, and unknown subclass: 0.2%), 5.7% were stage II, 10.9% were stage III (stage III A: 3.7%, III B:1.0%, III C1: 4.4%, III C2: 3.9%, and unknown subclass: 0.7%) and 7.4% were stage IV (stage IV A: 0.3%, IV B: 6.9%, and unknown subclass: 0.2%).
Histologic types (Table 2) . With regard to histological types of endometrial cancer, endometrioid adenocarcinoma occurred in 81.7% of the patients and was most common. The other histological types were serous adenocarcinoma (5.4%), clear cell adenocarcinoma (2.2%) and mixed carcinoma (2.5%). Carcinosarcoma was observed in 4.8% of patients with endometrial cancer. Treatment (Fig. 4) . With regard to endometrial cancer treatment methods, surgery alone was performed for 58.5% of the patients and was the most common therapy, followed by surgery + chemotherapy + hormone therapy (36.0%). Surgery + radiotherapy was performed for 0.9% of the patients, chemotherapy alone or in combination with hormone therapy was used for 2.1% of the patients, and radiotherapy alone was administered to 1.1% of the patients.
Ovarian cancer
Age distribution (Fig. 5) . The age distribution of patients with ovarian cancer was as follows: 1227 (19.1%), 1557 (24.2%) and 1809 (28.2%) patients in the age group of 40-49, 50-59 and 60-69 years, respectively. These results suggested that ovarian cancer is most common among women in their 50s and 60s. Histologic types (Table 3) . With regard to histological types of ovarian cancer, epithelial and mesenchymal tumors occurred in 95.5% of the patients. Serous adenocarcinoma, which is a representative histologic type of epithelial tumors, was presented in 38.3% of patients, clear cell adenocarcinoma in 23.0%, endometrioid adenocarcinoma in 16.7% and mucinous adenocarcinoma in 9.7%. The percentages of patients with sex cord stromal and germ cell tumors were 0.2% and 4.3%, respectively.
Treatment (Fig. 6 ). With regard to ovarian cancer treatment methods, surgery + adjuvant chemotherapy was performed for 69.9% of the patients and was the most common therapy, followed by surgery alone (22.1%) and chemotherapy alone (0.8%). In addition, surgery + adjuvant chemotherapy + targeted therapy was performed in 6.7% of the patients. (Table 4) . With regard to histologic types of ovarian borderline tumors, mucinous adenocarcinoma occurred in 52.5% of patients and was the most common histology, followed by serous adenocarcinoma (21.7%), endometrioid adenocarcinoma (2.4%) and mixed-type adenocarcinoma (5.5%). Granulosa cell tumor and immature teratoma (G1 and G2) were found in 8.2% and 3.3% of the patients, respectively.
Ovarian borderline tumors
Treatment. With regard to ovarian borderline tumor treatments, surgery alone was performed for 94.1% of the patients and was the most common treatment, followed by surgery + adjuvant chemotherapy, for 5.8% of the patients.
Annual treatment report for 2010
Cervical cancer
Overall survival (OS) by clinical stage (Fig. 7) . Survival based on cervical cancer clinical staging is shown in (P < 0.0001), stages II and III (P < 0.0001) and stages III and IV (P = 0.0002).
OS by histologic type (Fig. 8) . Survival by histologic type for patients with cervical cancer is shown in Fig. 8 . The 5-year survival was 78.5% for patients with squamous cell carcinoma, 75.8% for adenocarcinoma, 83.7% for adenosquamous carcinoma and 57.8% for others. Patients with squamous cell carcinoma showed good survival, with a significant difference compared to those with adenocarcinoma (P = 0.0236) and other histologic types (P < 0.0001). No significant difference in survival rate was observed for patients with squamous cell carcinoma compared to those with adenosquamous carcinoma (P = 0.1814). In addition, patients with adenocarcinoma showed a significant difference in survival compared to those with adenosquamous carcinoma (P = 0.0246), but did not significantly differ from other histologic types (P = 0.4051). There was a significant difference in survival between patients with adenosquamous carcinoma and those with other histologic types (P < 0.0001).
Endometrial cancer
OS by surgical stage of endometrial cancer (Fig. 9) 26.0%). Significant differences in survival were seen between stages I and II (P < 0.0001), stages II and III (P < 0.0001) and stages III and IV (P < 0.0001).
OS by histologic type of endometrial cancer (Fig. 10) .
The 5-year survival by histologic type for patients with endometrial cancers was 95.4% for G1 endometrioid adenocarcinoma (n = 2467), 87.3% for G2 endometrioid adenocarcinoma (n = 1087), 71.0% for G3 endometrioid adenocarcinoma (n = 518), 57.1% for serous adenocarcinoma, 65.3% for clear cell carcinoma, and 51.9% for carcinosarcoma. Patients with G1 endometrioid adenocarcinoma showed good survival with a significant difference compared to patients with G2 endometrioid adenocarcinoma, G3 endometrioid adenocarcinoma, serous adenocarcinoma, clear cell carcinoma and carcinosarcoma (P < 0.0001). Similarly, patients with G2 endometrioid adenocarcinoma showed good survival with a significant difference compared to those with G3 endometrioid adenocarcinoma, serous adenocarcinoma, clear cell adenocarcinoma and carcinosarcoma (P < 0.0001). Although patients with G3 endometrioid adenocarcinoma showed good survival with a significant difference compared to those with clear cell carcinoma (P < 0.0001), they did not show a significant difference from patients with serous adenocarcinoma (P = 0.2305) or carcinosarcoma (P = 0.3168). Patients with clear cell adenocarcinoma showed good survival with a significant difference compared to those with serous adenocarcinoma and carcinosarcoma (P < 0.0001).
Ovarian cancer (surface epithelial-stromal tumors)
OS by surgical stage of ovarian cancer (Fig. 11) . 61.3%, and III C: 42.6%), and 36.2% for those with stage IV. Survival was significantly different between stages I and II (P < 0.0001), stages II and III (P < 0.0001) and stages III and IV (P < 0.0001). Although the above analysis of prognosis did not include patients who received neoadjuvant chemotherapy, the 5-year survival of these patients was 42.0%.
OS by histologic type of ovarian cancer (Fig. 12) . In the 5-year survival by histologic type for patients with ovarian cancer, patients with serous adenocarcinoma had a poor prognosis, with a significant difference from those with mucinous adenocarcinoma (P < 0.0001), endometrioid adenocarcinoma (P < 0.0001) and clear cell adenocarcinoma (P < 0.0001). Of the histologic types of ovarian cancer, endometrioid adenocarcinoma showed the best prognosis, which was significantly different from those for mucinous adenocarcinoma (P < 0.0001) and clear cell adenocarcinoma (P = 0.0339).
Discussion
This study investigated the 2015 gynecological malignancy trends in Japan and analyzed the prognosis of gynecological malignancies for which treat- 3 This suggested that the increase was not only due to an increase in the number of participating institutions (2014: 411 and 2015: 430 institutions), but also due to the increasing prevalence of gynecological malignancies in Japan. The increase in the number of registered patients was particularly significant for endometrial cancer, which exceeded 10 000 patients in 2015.
Use of the FIGO 2008 staging system started in 2012 to register the cervical and endometrial cancer stages. There was no change in the registration of stages in 2015 or in the number of registered patients by stage, compared to that in the 2014 Annual Patient Report. 3 Meanwhile, although the use of the FIGO 2014 staging system began in 2015, there was no notable change in the respective percentages of registered patients with stages I-IV ovarian cancer (2014; stage I: The staging of patients with cervical cancer, endometrial cancer, and ovarian cancer whose treatment was initiated in 2010 was performed using the FIGO 1998 staging system. Prognoses were analyzed using Kaplan-Meier, log-rank and Wilcoxson tests. Data from institutions where the percentage of patients lost to follow-up exceeded 20%, according to follow-up study reports, were not used in the treatment outcome analyses. Among patients with a known prognosis, the 5-year survival (all the stages included) was 70.0%, 76.1%, and 59.5% for cervical, endometrial and ovarian cancers, respectively. Compared to the 2009 treatment outcomes (cervical cancer: 69.8%, endometrial cancer: 75.6% and ovarian cancer: 79.7%), 3 there was no notable change in the values for cervical cancer and endometrial cancer; however, the 5-year survival for ovarian cancer decreased. These data cannot be compared naively, and it may be possible that this selection of cases was influenced by a selection bias. Moreover, it is difficult to compare the rate of survival for ovarian cancer in this study to those in oversea countries because the collection of data was different way. However, we found the global study comparing cancer survival internationally. It reported that the 5-year survival for ovarian cancer in Japan was almost equivalent to those in oversea countries such as Korea and USA. 4 With regard to data management, re-evaluation and improvement are performed by the Tumor Registration Committee, and inquiries are carried out to improve the quality of the data, which are then made to be handled properly by the registration facility.
In this study, the Annual Patient Report for 2015 regarding gynecological malignancies (cervical cancer, endometrial cancer, ovarian cancer and ovarian borderline tumor) and the Annual Treatment Report for 2010 regarding the outcome of patients who started treatment in 2010 were presented. These data are very valuable for knowledge about the gynecological malignancy trends in Japan. In the future, we plan to develop a new study based on these data.
